Light-chain deposition disease (LCDD) reoccurs almost invariably after renal transplantation, leading to early graft loss. We report a case of LCDD with monoclonal gammopathy of renal significance diagnosed in the post-transplant period in a 28-year-old male and we discuss the diagnostic and therapeutic challenges in the clinical course.
Introduction
Monoclonal gammopathy of renal significance (MGRS) is a recently introduced clinical term aimed at identifying patients with a small B-cell clone that does not meet criteria for myeloma or lymphoma. However, it causes significant renal diseases resulting from a deposition of monoclonal immunoglobulins (MIg). MGRS is associated with a wide spectrum of glomerulopathies, classified by the type, localization, and organization of the deposited MIg. 1 Light-chain deposition disease (LCDD) is characterized by the deposition of monoclonal, amorphous, non-Congophilic light chains in Correspondence to:
Dr. Raja Aoudia, Department of Internal Medicine A, Laboratory of Renal Pathology -LR00SP01, Charles Nicolle Hospital, Tunis, Tunisia. E-mail: rajoi2000@yahoo.fr multiple organs that do not exhibit a fibrillar structure when examined on electronic microscopy. 2 Renal involvement is a constant feature which includes renal failure, hypertension, proteinuria, hematuria, or nephrotic syndrome. If not treated, most patients with kidney involvement rapidly develop an end-stage renal disease (ESRD). 3, 4 Median survival of patients with LCDD and ESRD on dialysis is four years. 5 Renal transplantation for LCDD is associated with a high risk of disease recurrence and allograft failure. Renal transplantation is not forbidden, it remains an option for a few selected patients. 6 The aim of our work is to present a case of LCDD with MGRS diagnosed in the posttransplant period and to discuss the diagnostic and therapeutic challenges in the clinical course.
Case Report
Informed consent was obtained from the
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patient before presenting the report.
At the age of 28, an Algerian man was diagnosed with a stage-5 chronic renal failure. Renal biopsy showed a significant fibrosis. No tissue was available for immunofluorescence (IF) study. He was treated by hemodialysis (HD) for four months, then underwent a liverelated renal allograft transplantation in Jordan in August 2014. The donor was his 30-yearold brother. The posttransplant period was initially uneventful with a baseline serum creatinine of 100 µmol/L on triple drug immunosuppression (prednisone, tacrolimus and mycophenolate mofetil). In September 2015, he developed renal failure. Blood tests showed acute kidney injury with serum creatinine of 214 µmol/L. First proteinuria was negative then rapidly progressed to 2.8 g/day after two weeks. Ultrasonography showed normal-sized graft without urinary tract obstruction. An allograft biopsy was performed for the indication of graft proteinuria and a mild graft dysfunction. Light microscopy showed no evidence of rejection, but the glomeruli displayed minimal mesangial expansion with a small mesangial nodular sclerosis in one glomerulus ( Figure 1 ). Congo red staining was negative. The IF showed strong staining for kappa () light chain in the mesangial region along the glomerular and the tubular basement membrane ( Figure 2 ). There was no staining for, IgG, IgA, IgM, C3, C1q and complement lambda () light chain. The C4d was negative. Hence, we evoked the pathological diagnosis of LCDD. No tissue was available for electron microscopy. According to the data of the biopsy, we carried out further investigations: total protein was 49 g/L, serum albumin was 31 g/L, and gammaglobulinemia 3.5 g/L. A serum and urine electrophoresis and immunofixation isolated monoclonal kappa LC gammopathy, with serum-free kappa chains at 480 mg/L (N: 3.3-19.4) and  at 26.6 mg/L (N: 5.71-26.3) and / ratio at 18 (N: 0.26-1.65). Serum ß2 microglobulin was 10.9 mg/L (N: 1-2.5). Baseline liver tests and serum calcium were normal. Bone marrow biopsy showed 5% plasma cells and no osteolytic lesions were identified by a full skeletal survey. As bortezomib was not available, the patient had two cycles of dexamethasone at a dose of 40 mg/day for four days.
Because of a greater decline in his renal function (serum creatinine 897 µmol/L) a second allograft biopsy was performed two months later. All the glomeruli now showed diffuse nodular glomerulosclerosis (Figure 3) . The nodules were positive on periodic acid-Schiff's stain and were not congophilic. There were no features suggestive of rejection, and C4d staining was negative in the peritubular capillaries. There were severe fibrosis and tubular atrophy with thickening of the tubular basement membranes. IF staining showed kappa uptake in the glomerular capillary walls and mesangium along tubular basement membrane and an arterial wall staining (Figure 4) , while lambda was negative. There was no deposition of any other antisera (IgG, IgM, IgA, C3, and C1q) studied. The patient returned to Algeria where he received Bortezomib without recovering renal function and he remained on chronic HD.
Discussion
Our observation shows several points of interest and raises many questions. Our patient was only 28 years old, and it has been reported that LCDD often develops in males from the 5 th and 6 th decades of life with age range 24-94 years and one-third of cases occurring in less than 50-year-old patients. 7 The diagnosis is made after transplantation from the graftbiopsy, thanks to the systematic use of antiserums of light chains kappa and lambda. The question is whether it is recurrent or de novo LCDD? The initial nephropathy in our case was unknown. The diagnosis could not be made despite kidney biopsy. The hallmark of LCDD on renal biopsy is nodular sclerosing glomerulopathy with a variable thickening of the glomerular, tubular, and vascular basement membranes brightly eosinophilic and strongly periodic acid-Schiff-positive material. IF is characteristic and shows intense (usually kappa) diffuse linear staining of renal basement membranes throughout all the compartments of the kidney. Electron microscopy shows amorphous, nonfibrillar, finely granular, punctuate, highly electrodense deposits, 8, 9 In light microscopy, our patient showed advanced lesions. No particular nephropathy prior to transplant kidney biopsy was mentioned. Pretransplant assessment and transplantation were done in Jordan, we do not know if a monoclonal gammopathy was sought or not. However, it is difficult to think that it was de novo LCDD since clinical experiences from the few patients with LCDD who underwent transplantation showed that failure to control light-chain production resulted in rapid recurrence of the disease in the allograft. Leung et al 6 reviewed seven patients of LCDD who underwent renal transplantation. One patient had an associated multiple myeloma and received melphalan pretransplant, whereas the remaining six were hematologically classified as monoclonal gammo- pathy of unknown significance (MGUS) and did not receive any chemotherapy. Five of the seven patients developed a recurrence with a rapid median time of recurrence of 33.3 months (2.9-45.9 months) including four patients with MGUS. The median time to reach ESRD after recurrence was 10.9 months, and the overall median graft survival was 37.3 months. In our patient, LCDD occurred within 13 months after transplantation. Graft loss was also rapid, two months after the diagnosis of LCDD and 15 months after transplantation. Here, we emphasize the rapid progression of the disease, which impressed us on the second allograft biopsy. It showed diffuse nodular sclerosis and interstitial fibrosis and a tubular atrophy absent on the first allograft biopsy performed only two months earlier.
Treatment aims at controlling plasma cell proliferation, maintaining kidney function, and increasing survival by the use chemotherapy. There is no standard therapy because of the rare incidence of LCDD. Various treatment regimens have been used to suppress lightchain production and manage existing organ dysfunction. Melphalan combined with prednisone has been used for LCDD with or without multiple myeloma, but the response is limited. 10 There are some reports of recurrent LCDD in patients after unrelated-living-donor renal transplantation treated successfully with Bortezomib. 1, 7, [11] [12] [13] Hence, Bortezomib can stabilize renal function in patients with LCDD. However, when substantial chronic renal damage had already occurred, as in our patient, renal dysfunction is usually progressive. Kidney transplantation should be reserved for patients, in whom the light-chain production is controlled, and long-lasting remission is documented. In case of livingdonor kidney transplantation, both the donor and recipient must be thoroughly informed about the possibility of a recurrence and a potentially reduced lifespan of the allograft. Recurrence is common, and bortezomib may provide an alternative to currently available 13 treatment options in patients with LCDD recurrence after transplantation.
This case emphasizes the importance of identifying a kidney disease before transplantation, especially in young patients and potential recurrent nephropathies. When MGRS is diagnosed in the pre-transplant period, the paraprotein secreting clone can be optimally treated. Atfer transplantation, allo-graft biopsy is an essential tool to understand graft abnormalities and consequently ensure the followup of renal transplant patients. A proper histological analysis of all transplant biopsies, including light microscopy, immunohistochemistry and if possible electronic microscopy is essential to diagnose MGRS-related kidney diseases. Post-transplant management of recurrent LCDD is challenging. Larger prospective studies are needed to make strong recommendations regarding transplantation for this population of patients who appear to be at a high risk of a recurrence of the disease.
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